KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 146 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 3.32 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,304 | -25.5% | 6,944 | -1.9% | 0.00% | – |
| Q2 2023 | $12,491 | -63.9% | 7,079 | -20.5% | 0.00% | – |
| Q1 2023 | $34,643 | +15.5% | 8,906 | 0.0% | 0.00% | – |
| Q4 2022 | $30,000 | +42.9% | 8,906 | +134.3% | 0.00% | – |
| Q3 2022 | $21,000 | +31.2% | 3,801 | +4.3% | 0.00% | – |
| Q2 2022 | $16,000 | -40.7% | 3,644 | +0.1% | 0.00% | – |
| Q1 2022 | $27,000 | -18.2% | 3,642 | -29.0% | 0.00% | – |
| Q4 2021 | $33,000 | -73.4% | 5,132 | -75.8% | 0.00% | – |
| Q3 2021 | $124,000 | -5.3% | 21,235 | +67.1% | 0.00% | – |
| Q2 2021 | $131,000 | -5.8% | 12,705 | -4.1% | 0.00% | – |
| Q1 2021 | $139,000 | -61.3% | 13,251 | -42.8% | 0.00% | -100.0% |
| Q4 2020 | $359,000 | +5.6% | 23,169 | -0.4% | 0.00% | 0.0% |
| Q3 2020 | $340,000 | -28.7% | 23,268 | -7.5% | 0.00% | -50.0% |
| Q2 2020 | $477,000 | +43.2% | 25,168 | +44.9% | 0.00% | +100.0% |
| Q1 2020 | $333,000 | – | 17,368 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |